Colt DCS Publishes 2024 Sustainability Highlights Report
Achieved 90% renewable energy procurement across the global estate. Maintained EcoVadis Platinum rating to be placed in the top 1% of assessed companies. Winner of Best Colocation Provider Sustainability Innovation of the Year Award. LONDON, June...
Vietnamese EdTech Galaxy Education Raises Nearly US$10M from East Ventures and Other Investors
HO CHI MINH CITY, Vietnam, June 24, 2025 /PRNewswire/ -- Galaxy Education (GE), a Vietnamese education technology company, has secured nearly USD 10 million in funding from East Ventures and other investors, marking one of the largest EdTech...
Antaisolar Signs Over 2GW in Global Partnerships and Unveils Smart Tracker AT-Spark at SNEC 2025
XIAMEN, China, June 19, 2025 /PRNewswire/ -- From June 11–13, the 18th SNEC PV Power Expo was held in Shanghai, attracting global attention. Antaisolar showcased its flagship smart tracking system, AT-Spark, along with a full range of solar mounting...
BRI Named Indonesia's Largest Public Company in the Forbes Global 2000 List for 2025
JAKARTA, Indonesia, June 19, 2025 /PRNewswire/ -- PT Bank Rakyat Indonesia (Persero) Tbk, (IDX: BBRI), has once again achieved an international milestone by securing the 349th position among the world's 2,000 largest public companies in the Forbes...
RayNeo Launches X3 Pro: Redefining AR with Cutting-Edge Tech
SHENZHEN, China, May 28, 2025 /PRNewswire/ -- RayNeo, a trailblazer in consumer AR technology, today unveiled its revolutionary product lineup at the "See the Extraordinary" launch event, marking China's ascendancy in the global XR arena. The...
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis...
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses...